Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

NCT04499924 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: tucatinib
DRUG: trastuzumab
DRUG: ramucirumab
DRUG: paclitaxel
OTHER: tucatinib placebo
OTHER: trastuzumab placebo

Sponsor

Seagen Inc.